Rucaparib Production Cost Reports

The report provides a detailed analysis essential for establishing a Rucaparib production plant. It encompasses all critical aspects necessary for Rucaparib production, including the cost of Rucaparib production, Rucaparib plant cost, Rucaparib production costs, and the overall Rucaparib production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a Rucaparib production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Rucaparib is an oral targeted chemotherapy drug that is used to treat certain types of cancer, like ovarian and prostate cancer. It works by blocking a specific protein in cancer cells that helps repair their damaged DNA. It is used to treat and maintain therapy for recurrent high-grade epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer in adults who have responded to platinum-based chemotherapy. It is also approved to treat metastatic castration-resistant prostate cancer in patients who have undergone prior therapies.

It is a valuable treatment option for cancers with these specific genetic features. It has been approved by health authorities and its common side effects include feeling tired or weak, nausea (feeling sick), vomiting, constipation or diarrhoea, loss of appetite, and changes in taste. 

The market for Rucaparib is driven by the increasing number of cancer cases worldwide. Its utilisation in ovarian and breast cancers contributes to its usage as an effective treatment. Regulatory approvals from the FDA support its use in maintenance therapy for ovarian cancer, which boosts its market growth. The investments in research and development, and rising awareness among doctors and patients about targeted cancer therapies, expand its market.

Also, improving healthcare infrastructure in regions like the Asia-Pacific improves access and applications. The industrial Rucaparib procurement is affected by factors likes fluctuating raw material prices, regulatory changes (regulatory approvals and updates from major health authorities like the FDA, EMA, and MHRA), and supply chain logistics.

Raw Material for Rucaparib Production

According to the Rucaparib production plant project report, the key raw materials used in the production of Rucaparib include 8-fluoro-4,5-dihydro-1H-azepino[5,4,3-cd]indol-6-one ( or 8-F-azepinoindolinone) -Cesium Carbonate-Palladium Tris(Dibenzylideneacetone)-Copper Nitrate-(4-Bromo-N-Methylbenzylamine).

Production Process of Rucaparib

The extensive Rucaparib production cost report consists of the following major industrial production process:

• From 8-F-azepinoindolinone: The production of Rucaparib starts with 8-F-azepinoindolinone, where it is mixed with cesium carbonate, palladium catalyst, copper nitrate, and DMA. After that, 4-bromo-N-methylbenzylamine is added to the mixture and heated and stirred. After that, sodium bicarbonate solution is added to the reaction mixture, and the product is separated. Finally, the crude product is purified using chromatography to get Rucaparib as the final product.

Rucaparib is a yellow to pale yellow solid that has the molecular formula of C19H18FN3O and a molecular weight of 323.36 g/mol. It is an azepinoindole compound classified as a poly (ADP-ribose) polymerase (PARP) inhibitor used in cancer therapy. Its melting point is between 187 to 189 degree Celsius, and it has a predicted boiling point of around 625 degree Celsius. It is slightly soluble in solvents like DMSO and methanol. It is achiral, with no defined stereocenters and shows moderate density around 1.281 g/cm³. It contains fluorine and is characterised as an organofluorine and secondary amino compound. All these physical and chemical properties make it useful in targeted cancer treatments.